
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals exhibits a robust compounding business model that effectively leverages cash inflows for further deal-making, highlighting its unique position within the small- to mid-cap biotechnology sector. The company anticipates strong product launches for Filspari and Ohtuvayre, which are expected to drive significant growth alongside contributions from more stable revenue sources. These factors collectively point to a positive trajectory in Ligand’s financial performance, reinforcing a favorable outlook for the company’s stock.
Bears say
Ligand Pharmaceuticals Inc faces a negative outlook primarily due to the potential underperformance of its royalty assets, which may not meet existing expectations. Concerns regarding the durability of intellectual property for key assets, combined with the possibility that clinical-stage royalty assets may fail to receive approval, further contribute to the pessimistic assessment. Additionally, anticipated future terms of agreements may be less favorable, alongside the risk that commercial partners could encounter unforeseen challenges, potentially impacting the company's overall financial stability.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares